control priorities for potential invasive species could be based on easily available data about natural history and evolutionary ecology. We propose four guidelines for identifying such invasives.
An exotic organism may be more likely to invade and cause disruption the greater its rate of reproduction; the greater its dispersal ability; the closer (phylogenetically) its preferred food in its native range is to an abundant taxon in the new range; and the farther away (phylogenetically) its predators and pathogens are in its native range from those in its new range.
For example, the red turpentine beetle (Dendroctonus valens) is not particularly disruptive in its native range in North America because it attacks only trees that are already weakened. In China it attacks and kills healthy trees (Z. Yan et al. Biodivers. Conserv. 14, 1735 -1760 2005) . The reasons for this beetle's success as an invasive include its high dispersal and reproductive rates, its affinity for Chinese pines closely related to those it feeds on 'at home' , and the lack of predators or pathogens phylogenetically similar to ones found in North America. 
Manuel Lerdau

Nuclear winter was and is debatable
Alan Robock's contention that there has been no real scientific debate about the 'nuclear winter' concept is itself debatable (Nature 473, 275-276; 2011) .
This potential climate disaster, popularized in Science in 1983, rested on the output of a onedimensional model that was later shown to overestimate the smoke a nuclear holocaust might engender. More refined estimates, combined with advanced three-dimensional models (see go.nature.com/ kss8te), have dramatically
All-male line-up yet again
Most prestigious prizes in science that are not set aside for women go primarily or only to men. The eight male 2010 Kavli prizewinners in astrophysics, nanoscience and neuroscience are the most recent examples (see go.nature.com/5xh17n).
The Kavli winners are accomplished and deserve their honours. But the frequency of all-male line-ups, and the number of meritorious women,
UK cancer genetics gets personal
There is a promising way in which personalized medicine can be incorporated into healthservice infrastructure (Nature 473, 253-254; 2011) . In the United Kingdom, the charity Cancer Research UK is leading a partnership with AstraZeneca, Pfizer and the government's Technology Strategy Board to help the National Health Service to adopt a consistent approach to reduced the extent and severity of the projected cooling.
Despite this, Carl Sagan, who co-authored the 1983 Science paper, went so far as to posit "the extinction of Homo sapiens" (C. Sagan Foreign Affairs 63, 75-77; 1984) . Some regarded this apocalyptic prediction as an exercise in mythology. George Rathjens of the Massachusetts Institute of Technology protested: "Nuclear winter is the worst example of the misrepresentation of science to the public in my memory, " (see go.nature.com/yujz84) and climatologist Kerry Emanuel observed that the subject had "become notorious for its lack of scientific integrity" (Nature 319, 259; 1986).
Robock's single-digit fall in temperature is at odds with the subzero (about -25 °C) continental cooling originally projected for a wide spectrum of nuclear wars. Whereas Sagan predicted darkness at noon from a US-Soviet nuclear conflict, Robock projects global sunlight that is several orders of magnitude brighter for a Pakistan-India conflictliterally the difference between night and day. Since 1983, the projected worst-case cooling has fallen from a Siberian deep freeze spanning 11,000 degreedays Celsius (a measure of the severity of winters) to numbers so unseasonably small as to call the very term 'nuclear winter' into question. genetic testing for targeted cancer therapies, and to promote further research into personalized treatment.
Russell Seitz
The first phase will run from 2011 to 2013 and cost £5.5 million (US$8.8 million). The programme will model the processes required for routine testing of tumour molecular characteristics and for secure storage and retrieval of molecular and clinical data for research. It will involve seven Experimental Cancer Medicine Centres and 9,000 patients with one of six tumour types: breast, colorectal, lung, prostate, ovary and metastatic melanoma. Up to 22 mutations will be tested, with the aim of harmonizing practices across the centres and labs.
The second phase will establish a molecular diagnostics service to deliver high-quality, standardized tests for patients nationwide and to obtain routine consent for the collection, storage and research use of data on genetics, treatments and outcomes. 
